1. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). (December 2022) Authors: Zhang, J.; Hussein, M.; Kao, S.C-H.; Clay, T.D.; Singhal, N.; Kim, H.R.; Cho, E.K.; Shim, B.; Lee, Y.; Lee, G-W.; Zhao, J.; Yu, Y.; Sun, M.; Lin, C-B.; Yang, T-Y.; Chang, G-C.; Zheng, H.; Tan, W.; Spigel, D.R. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗